The role and regulatory mechanisms of IL-1 signaling has been extensively studied in a variety of infectious diseases, inflammation, and inflammation-related cancers, such as colon cancer, liver cancer, gastric cancer, cervical carcinoma, and lymphoma, but is still not well understood in breast cancer (BC) [12–14]. This evidence concerns the gene IL1B and breast carcinoma.